Exosomes were once assumed to be nothing more than waste products expelled by cells. They had no apparent significance or special trait. However, according to the latest research, these nanoparticles are an exact replica of their cell of origin, accelerating the process of gene transfer between cells.
In Simple terms, exosomes have the potential to act in the place of a parent cell all across the body, which could lead to their usage in targeted therapeutic medication delivery with further research. Exosomes are also smaller and less complicated than their host cells, which is worth mentioning. These characteristics provide hope for the biotech industry’s current untapped potential. It’s fascinating to learn about the potential of exosomes in cancer early detection as the study and discovery of their biological nature progresses.
Exosomes are membrane-bound extracellular vesicles produced in most eukaryotic cells’ endosomal compartments. Applications of exosomes are all associated with pregnancy, immune responses, viral pathogenicity, central nervous system-related diseases, cardiovascular disorders, and tumor growth. It effectively transfers biomolecules such as metabolites, proteins, and nucleic acids into target cells to modulate their biological response.
Exosomes are designed to deliver multiple therapeutic payloads, such as short interfering ribonucleic acids (RNAs), chemotherapeutic drugs, antisense oligonucleotides, and immunological modulators, to specific targets. Exosome vesicle-based liquid biopsy has the potential to be utilized in the prognosis and diagnosis of cancer and other disorders of patients.
The rising incidence of chronic disease, autoimmune disease, infectious disease, and cancer, and the spike in demands for molecular diagnosis, are major driving factors in the exosome diagnostic and therapeutic market share. Furthermore, continuous advancements in exosome technologies in drug discovery and development offer vital information about biological function and heterogeneity, enhancing the ability to access therapeutic and diagnostic potential of cancer and infectious disease. Therefore, advancements in healthcare technology boost the expansion of the global exosome diagnostic and therapeutic markets. According to Allied Market Research, the global exosome diagnostic and therapeutic market is anticipated to grow at a significant CAGR of 29.4% from 2021 to 2030.
As the exosome technology is advancing, market players have adopted two key strategies to provide access to modern therapies and diagnostics. These two strategies are new product launches and partnerships. Aethlon Medical, a healthcare firm, signed a partnership with the University of Pittsburgh on a National Institute of Health grant for offering head and neck cancer treatment in August 2020. Exosomes are nanoparticles generated in huge quantities by cancer cells that carry a tumor’s protein and genetic cargo, which boost cancer growth and immune suppression.
Furthermore, Exosome Diagnostics, a biotechnology firm, announced the release of an at-home ExoDx Prostate test kit in April 2020. The ExoDx Prostate (EPI) test is a genomic urine test that can help diagnose prostate cancer. The NCCN (National Cancer Comprehensive Network) guidelines for early diagnosis in men include this liquid biopsy test, which was previously covered in the VA Healthcare system because of a General Services Administration (GSA) award.
Author’s bio:
Vaishanavi Kumbalwar is a fun-loving, independent, unconventional and original thinker who loves to put her thoughts into words. She holds a bachelor’s degree in Mechanical Engineering and currently working as Senior Associate Content Writer at Allied Market Research. She thrives on challenges and loves to explore different writing styles to bring off her fondness for being a writer and blogger. She is an enthusiast of different cultures, places and cuisines and loves to travel off the tourist path and explore new things.
0 Comments